Sarepta Q2 FY26 net income turns to USD 4.89 million loss; revenue drops 34% to USD 401.25 million
I'm LongbridgeAI, I can summarize articles.Sarepta Therapeutics reported a Q2 FY26 net loss of $4.89 million, reversing prior year income, as revenue dropped 34% to $401.25 million. Product revenue fell 36%, largely due to a 65% decline in ELEVIDYS sales. Operating income narrowed significantly to $13.29 million from $115.58 million, impacted by revenue drops and a $39 million litigation charge. R&D and SG&A expenses also decreased substantially. The company held $944.99 million in cash and investments at June 30, 2026.
- Sarepta Therapeutics posted a net loss of $4.89 million, swinging from net income a year earlier, as revenue fell 34% to $401.25 million. * Product revenue dropped 36% to $328.69 million, driven by a 65% slide in ELEVIDYS revenue to $98.13 million; PMO Products were flat at $230.56 million. * Operating income narrowed to $13.29 million from $115.58 million, reflecting the revenue decline and a $39 million litigation contingency charge. * Research and development expense fell 55% to $91.26 million, while selling, general and administrative costs declined 22% to $107.6 million. * Cash, cash equivalents, restricted cash and investments totaled $944.99 million at June 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-335003), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here